MedElevator Войти в исследования
← Поиск публикаций

DOI 10.56875/2589-0646.1117

Медицинская библиотека · Hematology/oncology and stem cell therapy · 2024

Predicting Stage Progression in Binet Stage a Chronic Lymphocytic Leukemia.

Alshemmari Salem H, Almazyad Mazyad, Alsarraf Ahmed, Kunhikrishnan Anita, Isaac Asha M, Kaempf Andy

СтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

The variable clinical course of chronic lymphocytic leukemia (CLL) and the lack of consensus on follow-up and treatment strategies have necessitated a prognostic model for identifying high-risk patients at the time of diagnosis.

METHODS

We involved a retrospective analysis of demographic and clinical characteristics of 212 patients diagnosed with Binet stage A CLL and thus eligible for risk stratification by both the International Prognostic Score for Early-stage CLL (IPS-E) and the alternative IPS-E (AIPS-E). We evaluated the applicability of these prognostic indices in our young, Middle Eastern cohort (median age 59 at diagnosis).

RESULTS

During the study period with a median follow-up of 3.5 years, 67 patients (32 %) experienced progression to first treatment and cumulative incidence of treatment was 13 % at 1 year and 28 % at 3 years after diagnosis. Sixty-nine (51 % of the 136 with a known value) patients harbored an unmutated immunoglobulin heavy chain gene (IGHV) and 21 (10 %) an 11q or 17p deletion with 11 % lacking FISH results. For each early-stage CLL prognostic index, more patients were identified as high-risk for disease progression (51 % of 124 patients evaluable for IPS-E; 42 % of 109 patients evaluable for AIPS-E) than intermediate-risk and low-risk. Multivariable models involving the IPS-E and AIPS-E components revealed that unmutated IGHV and elevated absolute lymphocyte count were significant predictors of earlier treatment requirement. Both prognostic scores were discriminative of time to first treatment (log-rank p < 0.001; c-statistics of 0.74 for IPS-E and 0.69 for AIPS-E).

CONCLUSION

Although clarity on clinical behavior with regard to initiation of treatment remains elusive, IPS-E and AIPS-E are valuable tools for identifying high-risk patients.

Для цитирования: Alshemmari Salem H, Almazyad Mazyad, Alsarraf Ahmed, Kunhikrishnan Anita, Isaac Asha M, Kaempf Andy. Predicting Stage Progression in Binet Stage a Chronic Lymphocytic Leukemia.. Hematology/oncology and stem cell therapy. 2024. DOI: 10.56875/2589-0646.1117.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.